We read with interest the recent article by Buoni et al1 in which the authors described a striking improvement in the ataxia in a 3-year-old boy with ataxia-telangiectasia (AT) during treatment with inhaled betamethasone. In spite of the favorable response to the drug, the authors expressed their concern about the adverse effects observed during the trial (weight gain and a cushingoid appearance) and about the safety of betamethasone in an already immunocompromised patient.1
Gazulla J, Benavente I, Sarasa M. New Therapies for Ataxia-Telangiectasia. Arch Neurol. 2007;64(4):607–608. doi:10.1001/archneur.64.4.607-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.